Unaudited Financial Results for the first quarter and three months ended June 30, 2026

July 31, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Outcome of the Board Meeting Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we would like to inform that based on the recommendation of the Audit Committee, the Board at its meeting held today has, inter alia, approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the first quarter and three months ended June 30, 2026. The said financial results are enclosed herewith. In terms of Regulation 47 of the Listing Regulations, the Company will publish an advertisement for unaudited standalone and consolidated financial results for the first quarter and three months ended June 30, 2026. The above results along with limited review reports are also being made available on the website of the Company at www.coronaremedies.com A Press Release on financial results which is being submitted to the media, is also enclosed herewith. The Board meeting commenced at 03:00 p.m. and concluded at 04:00 p.m. You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a PRESS RELEASE CORONA Remedies delivers a strong start to FY 27, with a Revenue growth of 21.9% and a PAT growth of 30.1% Y-o-Y for Q1FY27, driven by robust Brand Building and Operaonal Excellence Ahmedabad | July 31, 2026 CORONA Remedies Limited, a leading India-focused branded pharmaceucal company, announced its unaudited financial results for Q1FY27, delivering robust revenue and resilient margins, supported by consistent brand-building, focus on engine brands and enhanced operaonal efficiencies. Key Operaonal & Financial Highlights  Delivered ₹ 422.4 Cr revenue for Q1FY27 registering a growth of 21.9% Y-o-Y supported by execuon excellence and focused brand building iniaves.  PAT for Q1FY27 stood at ₹ 60.1Cr, a growth of 30.1% Y-o-Y. PAT margins for Q1FY27 stood at 14.2%, an increase of 90 bps Y-o-Y. Financial Performance Snapshot: Particulars (₹ in Cr) Q1FY27 Q1FY26 Y-o-Y % Growth Revenue from Operations 422.4 346.5 21.9% EBITDA 93.1 69.8 33.5% EBITDA Margin 22.0% 20.1% 190 bps Profit After Tax 60.1 46.2 30.1% Profit After Tax Margin 14.2% 13.3% 90 bps Key Business Highlights:  Outpacing IPM Growth1: CORONA connues to be the fastest growing company among top 30 companies of IPM for last 6 consecuve months, as per MAT June’26. CORONA has outperformed market by 1.9 mes as per MAT June’26.  Market Rank Progression1: Rank moves 3 places up in a year and reaches at 26th Rank as per MAT June’26 and for the quarter (We were at 29th Rank as of MAT June’25).  Therapy Leadership1: CORONA stands at 5th rank in Gynaecology; reflecng our commitment and therapy leadership in the segment.  Inauguraon of Female Hormone Plant: Inaugurated and iniated the commercializaon of our EU-GMP approved Female Hormone Manufacturing Facility based in Ahmedabad, on 30 June 2026.  Integraon of Wokadine (acquired brand): We have iniated the smooth integraon of Wokadine from the supply side and distribuon perspecve. 1: As per Pharmatrac June’26 Data Commenng on the performance for Q1FY27, Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “Q1 FY27 shows our commitment to consistent growth with operaonal excellence and brand building. With robust revenue growth and market rank improvement, we see posive outcomes of the strategies in place. We aim to move steadfast with our aligned focus on core therapies such as Women’s Healthcare, Cardio-diabetes, Pain Management and Urology. We are also strengthening ourselves in Inferlity and Biosimilar segment.” About CORONA Remedies Limited Founded in 2004, CORONA Remedies Limited is a leading India-focused pharmaceucal company engaged in developing, manufacturing, and markeng products across key therapeuc areas including women’s healthcare, cardio-diabetes, pain management and urology. The company operates WHO-GMP/EU GMP-cerfied manufacturing facilies and maintains strong innovaon capabilies through DSIR-approved R&D centers. Disclaimer: Certain statements contained in this document may be statements of future expectaons and other forward-looking statements that are based on management ‘s current view and assumpons and involve known and unknown risks and uncertaines that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representaves shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connecon with this document. This document does not constute an offer or invitaon to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connecon with any contract or commitment whatsoever. For further informaon, please contact Company Investor Relations Advisors CORONA Remedies Limited Strategic Growth Advisors Pvt Ltd. CIN: L24231GJ2004PLC044656 CIN: U74140MH2010PTC204285 Chetna Dharajiya – Company Secretary Sagar Shroff / Tanay Shah & Compliance Officer Email id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899